NKMAX
LIVE

Serial Number

97121020

Owner

NKMAX Co., Ltd.

Attorney

Deborah L. Corpus

First Use Date

Aug 5, 2019

Filing Date

Nov 11, 2021

Add to watchlist:

No watchlists yet
View on USPTO

NKMAX Trademark

Serial Number: 97121020 • Registration: 7146622

NKMAX is a trademark filed by NKMAX Co., Ltd. on November 11, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

NKMAX Co., Ltd. (12 trademarks)

6F/1F SNUH Health Care Innovation Park
Gyeonggi-do 13605 , KR

Entity Type: 03

Trademark Details

Filing Date

November 11, 2021

Registration Date

August 22, 2023

First Use Anywhere

August 5, 2019

First Use in Commerce

August 5, 2019

Published for Opposition

October 25, 2022

Goods & Services

Pharmaceutical preparations for animals for regulating the immune system and treating cancer; pharmaceutical preparations, namely, immunomodulators; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells for regulating the immune system and treating cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; stem cells for medical purposes; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of immune system related diseases and disorders

Development of cell therapy products; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes; medical and pharmacological research services; medical research services; development of biotechnology products; biotechnological research; cell separation research services; technological research in the field of cell therapy, medicine, pharmacology, biotechnology

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 6, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 6, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 6, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 6, 2024 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 22, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 22, 2023 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jul 19, 2023 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 18, 2023 CNPR
ASSIGNED TO EXAMINER
Jul 17, 2023 DOCK
STATEMENT OF USE PROCESSING COMPLETE
May 17, 2023 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 17, 2023 AITU
USE AMENDMENT FILED
Apr 27, 2023 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 27, 2023 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 20, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 25, 2022 NPUB
PUBLISHED FOR OPPOSITION
Oct 25, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 5, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 25, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 25, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 25, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 25, 2022 CNEA
ASSIGNED TO EXAMINER
Aug 22, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 18, 2021 NWOS
NEW APPLICATION ENTERED
Nov 15, 2021 NWAP